A new scenario in metastatic renal cell carcinoma: a SOG‑GU consensus

• S. Vázquez Estévez ^[1] ; U. Anido ^[4] ; M. Lázaro ^[2] ; O. Fernández ^[5] ; N. Fernández Núñez ^[1] ; N. de Dios Álvarez ^[2] ; V. Varela ^[4] ; B. Campos Balea ^[1] ; S. Agraso ^[2] ; M. C. Areses ^[5] ; L. Iglesias ^[5] ; M. Blanco ^[4] ; S. Maciá ^[6] ; L. M. Anton Aparicio ^[3]
  1. [1] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  2. [2] Hospital Álvaro Cunqueiro

     Hospital Álvaro Cunqueiro

     Vigo, España

     
  3. [3] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  4. [4] Medical Oncology Department, Complejo Hospitalario Universitario Santiago de Compostela, Trav. da Choupana, s/n, 15702 Santiago de Compostela, Spain
  5. [5] Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ramón Puga Noguerol, 54, 32005 Ourense, Spain
  6. [6] Oncology Medical Department, Pivotal, Calle Gobelas, no 19, 28023 Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 9, 2020, págs. 1565-1579
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background This article describes and compares approved targeted therapies and the newer immunotherapy agents.

    Materials and methods This article especially performs an in-depth review of currently available data for tivozanib, explain- ing its mechanism of action, its safety profile and its role as an efficacy drug in the management of renal cancer.

    Results Despite the fact that the treatment of advanced RCC has been dramatically modified in recent years, durable remis- sions are scarce and it remains a lethal disease. For first- and second-line therapy, there is now growing evidence to guide the selection of the appropriate treatment.

    Conclusions Several TKIs are standard of care at different settings. Among those approved TKIs, tivozanib has similar efficacy than others with a better safety profile. The use of prognostic factors is critical to the selection of optimal therapy.